At the time of writing, Verve Therapeutics Inc [VERV] stock is trading at $8.75, up 4.17%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VERV shares have gain 5.17% over the last week, with a monthly amount drifted -41.51%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, Verve Therapeutics Announces Updates on its PCSK9 Program. In a post published today on Yahoo Finance, Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101.
From an analyst’s perspective:
Verve Therapeutics Inc [NASDAQ: VERV] stock has seen the most recent analyst activity on April 08, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $15. Previously, Canaccord Genuity started tracking the stock with Buy rating on April 13, 2023, and set its price target to $29. On February 01, 2023, Cantor Fitzgerald initiated with a Neutral rating and assigned a price target of $21 on the stock. Goldman started tracking the stock assigning a Sell rating and suggested a price target of $13 on December 15, 2022. Credit Suisse initiated its recommendation with a Neutral and recommended $48 as its price target on October 06, 2022. Stifel upgraded its rating to Buy for this stock on August 25, 2022, and upped its price target to $56. In a note dated June 17, 2022, BMO Capital Markets initiated an Outperform rating and provided a target price of $48 on this stock.
For the past year, the stock price of Verve Therapeutics Inc fluctuated between $7.36 and $21.42. Currently, Wall Street analysts expect the stock to reach $21.5 within the next 12 months. Verve Therapeutics Inc [NASDAQ: VERV] shares were valued at $8.75 at the most recent close of the market. An investor can expect a potential return of 145.71% based on the average VERV price forecast.
Analyzing the VERV fundamentals
According to Verve Therapeutics Inc [NASDAQ:VERV], the company’s sales were 11.76M for trailing twelve months, which represents an 408.30% jump. Gross Profit Margin for this corporation currently stands at 0.11% with Operating Profit Margin at -18.98%, Pretax Profit Margin comes in at -16.99%, and Net Profit Margin reading is -16.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.38 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.49 points at the first support level, and at 8.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.89, and for the 2nd resistance point, it is at 9.03.
Verve Therapeutics Inc [VERV] reported earnings per share of -$0.69 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.82/share, meaning a difference of $0.13 and a surprise factor of 15.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.72 per share as compared to estimates of -$0.92 per share, a difference of $0.2 representing a surprise of 21.70%.
Ratios To Look Out For
It is important to note that Verve Therapeutics Inc [NASDAQ:VERV] has a current ratio of 17.24. Also, the Quick Ratio is 17.24, while the Cash Ratio stands at 5.57. Considering the valuation of this stock, the price to sales ratio is 58.44, the price to book ratio is 1.20.
Transactions by insiders
Recent insider trading involved Nickerson Joan, Chief Administrative Officer, that happened on Apr 02 ’24 when 1514.0 shares were sold. Chief Financial Officer, Dorval Allison completed a deal on Nov 29 ’23 to sell 554.0 shares.
